HCMB;Human Melanoma Cell Bowes;Bowes melanoma cells

Childhood T Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia
Invasive Ductal Carcinoma Not Otherwise Specified
Thyroid Gland Anaplastic Carcinoma Squamous Cell Carcinoma Pattern
High Grade Ovarian Serous Adenocarcinoma
Gastric Small Cell Neuroendocrine Carcinoma
Human Papilloma Virus-Related Cervical Squamous Cell Carcinoma
Splenic Marginal Zone B-Cell Lymphoma with Villous Lymphocytes
Epstein-Barr Virus-Related Burkitt s Lymphoma
Hereditary Thyroid Gland Medullary Carcinoma
Natural Killer Cell Lymphoblastic Leukemia or Lymphoma
Childhood Acute Differentiated Monocytic Leukemia
Epithelioid Cell Type Gastrointestinal Stromal Tumor
Squamous Cell Breast Carcinoma Acantholytic Variant
Childhood Acute Myeloid Leukemia with Maturation
Mediastinal Thymic Large B-Cell Cell Lymphoma
Childhood Precursor T Lymphoblastic Lymphoma
Undifferentiated Sarcoma - Not Otherwise Specified
Ovarian Small Cell Carcinoma, Hypercalcemic Type
Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Malignant Non-Hodgkin Lymphoma, Cleaved Cell
T-Cell Large Granular Lymphocyte Leukemia
Malignant Mixed Mesodermal (Mullerian) Tumor
Cervical Poorly Differentiated Adenosquamous Carcinoma

Transfected with a thymidylate synthase (TS) expressing vector.
Transfected with a thymidylate synthase (TS)-expressing vector conferring Blasticidin-S hydrochloride resistance.
Transfected with a luciferase (LUC) expressing vector.

H2 Blockers;Proton Pump Inhibitors;No Treatment;Antacids

Fifteen courses of FAMT (5-fluorouracil, cyclophosphamide, mitomycin C and chromomycin A)
cisplatin, 5-fluorouracil and chlorambucil treatment.
The patient had received sequential treatment with cisplatin and cyclophosphamide, cisplatin and etoposide and subsequently tamoxifen
Three courses of CAP; cyclophosphamide, adriamycin and cisplatin. Three courses of etoposide and cisplatin.
radiation, steroids, cytoxan and 5 fluorouracil
Six courses of CAP; cyclophosphamide, adriamycin and cis-platinum.
yclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP chemotherapy)
5 fluorouracil, doxorubicin and mitomycin C
treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin C
The patient was treated with RTG, methotrexate, adriamycin, vincristine, cytoxan, and aramycin C
MACOP-B; Methotrexate with Leucovorin rescue, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, and Bleomycin.
Chemotherapeutic treatment of incristine/adriamycin/cyclophosphamide alternating with ifosfamide/etoposide followed by high dose of carboplatin/ifosfamide/etoposide, followed by bone marrow transplant.;
MACOP-B scheme was started, and interrupted after 4 weeks because of disease progression.  The patient was then given chemoterapeutic treatment of ifosfamide, cytarabine, high-dose methotrexate and methylprednisolone.
Three courses of intraperitoneal cisplatin.
Chemotherapeutic treatment included cyclophosphamide, vincristine, high-dose methotrexate, dexamethasone, carmustine, etoposide, cytarabine, melphalane and rituximab.  Treatment also included radiotherapy of the abdominal tumor region.
Chemotherapeutic treatment of 4 cycles of cisplatin, doxorubicin, cyclophosphamide, etoposide.
The patient was treated with cytoxan, vincristine, methotrexate and radiation therapy
Combination chemotherapy with cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP).
CAP (Cyclophosphamide, Adriamycin, Cisplatin) and 5-Fluorouracil.
4 courses of cyclophosphamide (PEC), 3 courses of carboplatin plus interferon and 1 course of Taxol plus ifosfamide.
BEACOPP (32 Gy); 2 cycles of DHAP followed by BEAM; 3 cycles of rituximab, gemcitabine and dexamethasone.
Cytoxan, adriamycin, methotrexate and 5-fluorouracil.
1989: Combination chemotherapy of enocitabine, daunorubicin hydrochloride, 6-mercaptopurine (6-MP) and prednisolone. ;1990a: Combination chemotherapy of cytarabine, mitoxantrone, 6-MP and prednisolone followed by two consolidation courses of high-dose cytarabine therapy. ;1990b: Another course of combination chemotherapy.
Diemthyltrizenoimidazol carboxamide (DTIC) and levamisole.
Five courses of CAP; cyclophosphamide, adriamycin and cis-platinum.
transcatheter arterial embolization with lipoidol plus doxorubicin
3 cycles of chemotherapy treatment with eroposide, colchicine, methotrexate and vincristine
Sample obtained secondary to the treatment of nodular sclerosing Hodgkin disease with radiation and chemotherapy (DSMZ).
After a splenectomy, the patient was treated intermittently with hydroxyurea and busulphan. Therapy was changed to monthly courses of cyclophosphamide and cyto-sine arabinoside for approximately 2 years. After this intermittent treatment with hydroxyurea and busulphan was resumed. Upon diagnosis of blastic crisis the patient received high-dose of piperazinedione followed by autologous bone marrow rescue.
Sample taken 25 years after onset of myelodysplastic syndromes (MDS) and 2 years after chemotherapy with Ara-C (DSMZ).
Sample obtained at autopsy 8 months after initial diagnosis in early 1988. Initial treatment was radiotherapy to an abdominal mass attached to the small and large bowel, followed by combination chemotherapy (cis-platinum, ara-C, VP16 and dexamethasone). Following a remission of 4-months, a large malignant pleural effusion developed that was unsuccessfully treated with further chemotherapy.